Chugai Pharmaceutical Co Ltd Information Meeting on ENSPRYNG Subcutaneous Injection Transcript
Welcome, everyone. I am Katsuhiro Hara, ENSPRYNG Lifecycle Leader at Chugai Pharmaceutical Company Limited. I will give you the product overview of ENSPRYNG subcutaneous injection 120-milligram syringe.
Please turn to Slide 2. Therapeutic classification is pH-dependent binding humanized anti-interleukin-6 receptor, IL-6R, monoclonal antibody. The name of the product is ENSPRYNG subcutaneous injection 120-milligram syringe. A generic name is satralizumab, a genetic recombination. The packaging is, as shown on the slide, with 1 milliliter syringe placed in the box. The syringe is a preferred one as the liquid drug is in the syringe in advance and can be taken out and immediately be injected subcutaneously. Moreover, it is equipped with a system to prevent needle sticks called needle safety device, where after injection, the needle retracts into the barrel to ensure safety.
Please turn to Slide 3. This slide shows the involvement of IL-6 in the pathogenesis of neuromyelitis spectrum disorders, or NMOSD. As Dr. Fujihara will explain in more
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
